The $744M pre-tax expense for In-Process Research & Development (IPR&D) and milestones indicates significant spending on collaborations, licensing, and asset acquisitions to bolster its drug pipeline.
Filing excerpt
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquired IPR&D and milestones expense of $744 million on a pre-tax basis, representing an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kcapexIncreaseGet every 8-K signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/a3cfccd0-d582-4281-8999-4021ef237801 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "a3cfccd0-d582-4281-8999-4021ef237801",
"signal_type": "sec-8k",
"signal_subtype": "capexIncrease",
"detected_at": "2026-04-07T09:30:39.927+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "The $744M pre-tax expense for In-Process Research & Development (IPR&D) and milestones indicates significant spending on collaborations, licensing, and asset acquisitions to bolster its drug pipeline. This large-scale investment may create opportunities for vendors supporting M&A integration, R&D collaboration platforms, and financial management.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired IPR&D and milestones expense for Q1 2026",
"dollar_millions": 744
},
"summary": "AbbVie reports $744M expense for acquired R&D and milestones in Q1 2026, signaling major investment.",
"excerpts": "Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquired IPR&D and milestones expense of $744 million on a pre-tax basis, representing an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000011/abbv-20260403.htm",
"filing_date": "2026-04-03",
"filing_year": 2026,
"fiscal_year_end": "04/03",
"sales_relevance": "Budget available",
"signal_category": "financial"
}
}
curl https://signals.autobound.ai/v1/signals/a3cfccd0-d582-4281-8999-4021ef237801 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.